Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Newly discovered survival pathway explains stubborn EGFR-driven lung cancers

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene called EGFR (epidermal growth factor receptor).

21 Jan 2026

DLL3 on circulating tumor cells predicts tarlatamab success in lung cancer

A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer will experience a lasting response to a newly approved immunotherapy called tarlatamab.

14 Jan 2026

Durvalumab extends survival in small cell lung cancer but raises cost concerns

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living with small cell lung cancer (SCLC).

9 Jan 2026

Brazilian study shows liquid biopsies can expedite lung cancer care

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for expediting diagnoses and guiding patient treatment.

7 Jan 2026

Inflammation and immune suppression fuel aggressive SCLC behavior and spread

Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only five percent. Despite this poor prognosis, SCLC is initially highly responsive to chemotherapy.

30 Dec 2025

Whole-body imaging reveals where drugs bind at single-cell resolution

When you take a drug, where in your body does it actually go? For most medications, scientists can make only educated guesses about the answer to this question.

22 Dec 2025

Study finds a new protein target against KRAS-driven non-small cell lung cancer

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States.

18 Dec 2025

Highly sensitive CRISPR-based method designed to detect low-frequency cancer mutations

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA circulating in the blood.

9 Dec 2025

Receiving immunotherapy earlier in the day may improve survival in cancer patients

Receiving anticancer immunotherapy earlier in the day may help individuals with cancer live longer. That's according to a study published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

8 Dec 2025

Study links higher glycemic index diets with increased lung cancer risk

In this study, researchers examined whether people who follow higher-GI or higher-GL diets have different risks of developing lung cancer.

24 Nov 2025

Study offers new insights on patient care and lung cancer surveillance rates

Despite recommendations for posttreatment surveillance in lung cancer patients, there is wide variability in the follow-up care that lung cancer patients receive. A recent study, led by senior author Leah Backhus, MD, MPH, Professor of Cardiothoracic Surgery (Thoracic Surgery) in the Stanford Department of Cardiothoracic Surgery, offers new insights on patient care and lung cancer surveillance rates.

21 Nov 2025

Innovative CRISPR strategy resensitizes lung cancer to treatment

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in lung cancer.

17 Nov 2025

Enhancing the cancer-immunity cycle through innovative vaccines

Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in oncology toward harnessing the immune system's intrinsic ability to combat malignancies.

14 Nov 2025

Studies identify complementary approaches to overcome drug resistance in KRAS G12C–mutant lung cancer

Two companion studies published in Cancer Research from scientists at Moffitt Cancer Center identify distinct but complementary approaches to overcoming drug resistance in KRAS G12C–mutant non-small cell lung cancer.

31 Oct 2025

New drug can have a promising effect in cancer patients with active brain metastases

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising effect in patients with active brain metastases of various tumor types.

28 Oct 2025

Leveraging the power of T cells for more effective and durable cancer immunotherapies

T cells play central roles in the adaptive immune response against cancer. Their functional inactivation is a primary driver of tumor progression, making the reactivation of T cell function a main goal in immunotherapy.

24 Oct 2025

How COVID mRNA vaccines may make cancer treatments more effective

Researchers found that COVID-19 mRNA vaccines, when given within 100 days of starting immune checkpoint inhibitors, were linked to significantly longer survival in lung and melanoma cancer patients. The vaccines trigger a powerful type-I interferon response that primes tumors to become more responsive to immunotherapy.

23 Oct 2025

Biodesix announces expanded Bio-Rad Laboratories partnership agreement to develop Droplet Digital™ PCR high complexity assays

Biodesix, Inc., a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory submissions of in vitro diagnostic (IVD) assays to enable highly sensitive detection of multiple genomic markers focused on oncology applications, utilizing Bio-Rad's Droplet Digital™ PCR (ddPCR™) technology on Bio-Rad's QX600 platform.

23 Oct 2025

Oral targeted therapy shrinks tumors in over 70% of patients with HER2-mutant NSCLC

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by researchers at The University of Texas MD Anderson Cancer Center.

22 Oct 2025

Study shows mRNA-based COVID vaccines enhance effectiveness of immune checkpoint therapy

Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years after beginning treatment, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center.